Seagen Prevails in Patent Case Against Daiichi Sankyo
A jury in the U.S. District Court for the Eastern District of Texas has concluded that Daiichi Sankyo is in violation of a Seagen patent and must pay the company almost $42 million in damages.
Daiichi Sankyo’s cancer drug Enhertu (fam-trastuzumab deruxtecan-nxki) used Seagen’s patented antibody-drug conjugate (ADC) delivery technology, the jury found. Seagen also said it plans to seek additional royalty payments until the patent expires in November 2024.
The two companies are still in arbitration over the ownership of separate ADC technology used in Enhertu and other undisclosed drug candidates. A decision in the arbitration case is expected later this year.